This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Connor MJ, Shah TT, Horan G, Bevan CL, Winkler M, Ahmed HU. Cytoreductive treatment strategies for de novo metastatic prostate cancer. Nat Rev Clin Oncol. 2019;11:1–5.
Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2019;38:395–405.
Ross AE, Hurley PJ, Tran PT, Rowe SP, Benzon B, O’Neal T, et al. A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2019;14:1–0.
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet (Lond. Engl). 2018;392:2353–66.
Connor MJ, Ahmed HU. Adjuvant treatments to the local tumour for metastatic prostate cancer: assessment of novel treatment algorithms (IP2-ATLANTA) NCT03763253. https://clinicaltrials.gov/ct2/show/NCT03763253
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
MJC has received funding from the Wellcome Trust and University College London Hospital (UCLH) Charity. MW: None. HUA reports receipt of grant funding and personal fees from SonaCare Medical Inc, grant funding from Trod Medical, and grant funding and personal fees from Sophiris Bio Inc. HUA also receives core funding from the UK National Institute of Health Research Imperial Biomedical Research Centre and grants from Wellcome Trust, MRC (UK), Cancer Research UK, Prostate Cancer UK, The Urology Foundation, BMA Foundation and Imperial Healthcare Charity.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Connor, M.J., Winkler, M. & Ahmed, H.U. Cytoreductive cryotherapy for newly diagnosed oligometastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis 23, 537–538 (2020). https://doi.org/10.1038/s41391-020-0216-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41391-020-0216-4